NFE2L2 and breast cancer: Targeted inhibition of Nrf2 using siRNA or the pharmacological agent brusatol sensitized BC cells to cisplatin, inhibited BC cell migration and division, decreased xenografted tumor growth, and stimulated lymphocyte migration towards tumor tissues in mice in vivo.